CG Oncology Completes $120M Series E

▤ Summary

IRVINE, CA, CG Oncology today announced the close of an oversubscribed $120 million Series E financing round. The company has secured a total of over $200 million in funding to date. In connection with the financing, Brian Liu, M.D., Principal from Longitude Capital, will join the companys board of directors. CG Oncology is an oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer. At CG Oncology, we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life.

▦ Linked Companies